Your email has been successfully added to our mailing list.

×
0 0.00857286938981332 0.00857286938981332 0.00857286938981332 0.00857286938981332 0.00857286938981332 0.00857286938981332 0.00857286938981332
Stock impact report

Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 “Process B” for Fanconi Anemia

Rocket Pharmaceuticals, Inc. (RCKT) 
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: rocketpharma.com
Company Research Source: Business Wire
—Preliminary Phase 2 Data Anticipated in 2020— NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the first patient in the global Phase 2 registration-enabling study of RP-L102 “Process B” received investigational therapy. RP-L102 is the Company’s lentiviral vector (LVV)-based gene therapy for the treatment of Fanconi Anemia (FA).“The initiation of Rocket’s first Phase 2 trial is an important milestone for the company as well as patients throughout the world battling FA,” said Kinnari Patel, Pharm.D., MBA, Chief Operating Officer and Head of Development of Rocket. “With the recent feedback received from the FDA and EMA of MMC-resistance as the primary endpoint, we are optimistic about the prospect of benefiting patients and, if the data are positive, working towards BLA and MAA submissions.”The registration Show less Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
RCKT alerts

from News Quantified
Opt-in for
RCKT alerts

from News Quantified